Interim results of the Ph-negative acute lymphoblastic leukemia treatment in adult patients (results of Russian research group of ALL treatment (RALL))

An interim analysis of long-term treatment results for 202 patients with acute lymphoblastic leukemia (ALL), aged 15–60 years, received therapy according protocol ALL-2009 was shown. The basic principle of ALL-2009 was non-aggressive, but continued cytostatic exposure, as well as the reproducibility in a regional hematology centers. Long-term treatment results of ALL-2009 are 2 times higher than the previously obtained in adult ALL patients within the Russian clinical multicenter studies of adult ALL. The 5‑year overall survival of patients younger than 30 years was 73.6 %, relapse-free survival (RFS) – 71.5 %, compared with 52.7 % and 61.8 % in patients aged 30 years and older, respectively. In patients with B-precursor ALL with normal karyotype of blast cells significantly higher 5‑year RFS (82.1 %) compared to patients with abnormal karyotype (58.8 %) was registered. For T-ALL cytogenetic characteristics of blast cells had no prognostic significance. For patients with T-ALL important to perform autologous stem cell transplantation as a later consolidation, as this significantly reduce
relapse rate (from 33 to 0 %).

1. Goldstone A. H., Richards S. M., Lazarus H. M. et al. In adults with standardrisk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation / maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII / ECOG E2993). Blood 2008;111(4):1827–33.

2. Arnold R., Terwey T. H., Vuong G. L. et al. Allogeneic stem cell transplantation in adults with high risk acute lymphoblastic leukemia (ALL) In first remission (CR1): promising, but strongly influenced by ALL subtypes. Blood 2013;122(21):abstr. 3409.

3. Recommendations of the European working group for adult ALL. Editor in chief N. Goekbuget. UNI-MED Verlag AG, Kurfurstenallee 130, D-28211 Bremen, Germany.

4. Huang J., Zou D.-H., Li Z.-J. et al. An auto-SCT-based total therapy resulted in encouraging outcomes in adolescents and young adults with acute lymphoblastic leukemia: report from a single center of China. Bone Marrow Transplant 2012;47:1087–94.

5. Nachmann S., Sather H. N., Buckley J. D. et al. Young adults 16–21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment. Cancer 1993;71: 3377–84.

6. Shiffer C. A. Differences in outcome in adolescence and young adults with ALL: a consequence of better regimens? Better doctors? Both? JCO 2003;21:760.

7. Ram R., Wolach O., Vidal L. et al. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatricinspired regimens: systematic review and meta-analysis. Am J Hematol 2012;87(5):472–8.

8. Stock W., La M., Sanford B. et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Leukemia Group B studies. Blood 2008;112:1646–54.

9. Boissel N., Auclerc M. F., Lheritier V. et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of French FRALLE-93 and LALA-94 trials. JCO 2003;21:774–80.

10. de Bont J. M., Holt B., Dekker A. W. et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric versus adult protocols in the Netherlands. Leukemia 2004;18:2032–5.

11. Ramanujachar R., Richards S., Hann I. et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII / E2993) trials. Pediatr Blood Cancer 2007;48:254–6.

12. Testi A., Valsecchi M., Conter V. et al. Difference in outcome of adolescents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AIEOP) and adult (GIMEMA) protocols. Blood 2004;104(11): abstr. 539a.

13. Hallbook H., Gustafsson G., Smedmyr B. et al. Treatment outcome in young adults and children > 10 years of age with acute lymphoblastic leukemia in weden: comparison between a pediatric protocol and an adult protocol. Cancer 2006;107:1551–61.

14. Usvasalo A., Raty R., Knuutila S. et al. Acute lympnoblastic leukemias in adolescents and yaoung adaults in Finland. Haematol 2008;93(8):1161–8.

15. DeAngelo D.J., Stevenson K. E., Dahlberg S. E. et al. Long-term outcome of a pediatric-inspired regimen used for adults ages 18 to 50 with newly diagnosed acute lymphoblastic leukemia. Leukemia 2014 Jul 31. doi: 10.1038 / leu.2014.229. [Epub ahead of print].

16. Савченко В. Г., Паровичникова Е. Н., Исаев В. Г. и др. Лечение острых лимфобластных лейкозов взрослых как нерешенная проблема. Тер архив 2001;(7):6–15.

17. Karachunskiy A., Herold R., von Stackelberg A. et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia. Leukemia 2008;22(6):1144–53.

18. Laporte J. P., Yeshurun M., Fouillard L. et al. A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant. Leukemia 2004;18(10):1717–21.

19. Программное лечение заболеваний системы крови. Под ред. В. Г. Савченко. М.: Практика, 2012. С. 289–342.

20. Паровичникова Е. Н., Клясова Г. А., Исаев В. Г. и др. Первые итоги терапии Ph-негативных острых лимфобластных лейкозов взрослых по протоколу Научно- исследовательской группы гематологических центров России ОЛЛ-2009. Тер архив 2011;(7):11–7.

21. Паровичникова Е. Н., Савченко В. Г., Давидян Ю. Р. и др. Итоги лечения острых лимфобластных лейкозов взрослых по протоколу ОЛЛ-2005 как основа для новых исследований. Тер архив 2009; 7):8–15.

22. Gomez-Sequi I., Cervera J., Such E. et al. Prognostic value of cytogenetics in adult patients with hiladelphia negative acute lymphoblastic leukemia. Ann Hematol 2012;91:19–25.